Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 2Completed 1

Sponsor Class

OTHER 12INDUSTRY 7OTHER_GOV 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Stomach Neoplasms 3Rectal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 1

Interventions

Oxaliplatin 10Fluorouracil 6Irinotecan 5Docetaxel 5Capecitabine 5tislelizumab 4S 1 (combination) 4Paclitaxel 4Endoscopic Mucosal Resection 4XELOX 3Levoleucovorin 3Laparoscopy 3Folfox protocol 3sintilimab 2apatinib 2Proton Pump Inhibitors 2Gastroenterostomy 2Gastrectomy 2Clarithromycin 2Chemotherapy, Adjuvant 2Amoxicillin 2vactosertib 1titanium silicide 1pembrolizumab 1lenvatinib 1durvalumab 1bismuth tripotassium dicitrate 1anlotinib 1Trastuzumab 1Tranexamic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER_GOV × Stomach Neoplasms × Folfox protocol × Clear all
NCT03939962 2022-01-26

Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma

Henan Cancer Hospital

Phase 2 Unknown
60 enrolled
Gastrointestinal

Stomach Neoplasms

NCT02845908 2021-04-23

POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC

Fujian Cancer Hospital

Phase 2 Completed
90 enrolled
Gastrointestinal

Stomach Neoplasms

NCT04155671 2019-11-07

POF Versus FOLFOX Plus IP Paclitaxel in AGC

Fujian Cancer Hospital

Phase 2 Unknown
260 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡